Physician profile
Lily Lines
NPI 1306661921
$1,609.78
in general payments reported to CMS, 2019-2025
19 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $216.85 | 2025 | Sucraid |
| Janssen Biotech, INC. | $200.77 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $168.23 | 2025 | Entyvio, Eohilia |
| Abbvie INC. | $166.61 | 2025 | |
| Ardelyx, INC. | $138.77 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $122.88 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $117.62 | 2025 | Iqirvo |
| Lilly USA, LLC | $105.87 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $82.49 | 2025 | Dupixent |
| Genzyme Corporation | $59.27 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.27 | 2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $36.44 | 2025 | |
| Phathom Pharmaceuticals, INC. | $29.88 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $28.53 | 2025 | Injectafer |
| Orphalan INC | $23.60 | 2025 | Cuvrior |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $23.21 | 2025 | |
| Gilead Sciences, INC. | $15.45 | 2025 | Livdelzi |
| Celltrion USA INC. | $15.42 | 2025 | Vegzelma |
| Organon LLC | $14.62 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Lines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.